WAM
SCVX

Wolverine Asset Management’s SCVX Corp. SCVX Stock Holding History

Wolverine Asset Management’s Portfolio SCVX Stock Details SCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-278,400
Closed -$2.78M – 2721
2021
Q4 		$2.78M Sell
278,400
-124,245
-31% -$1.24M 0.03% 457
2021
Q3 		$4M Sell
402,645
-796
-0.2% -$7.89K 0.03% 327
2021
Q2 		$3.99M Sell
403,441
-21,985
-5% -$218K 0.03% 311
2021
Q1 		$4.19M Sell
425,426
-179,646
-30% -$1.88M 0.04% 268
2020
Q4 		$6.23M Sell
605,072
-23,078
-4% -$234K 0.05% 231
2020
Q3 		$6.28M Buy
628,150
+153,150
+32% +$1.55M 0.06% 195
2020
Q2 		$4.73M Buy
+475,000
New +$4.66M 0.05% 226

Other funds holding SCVX

MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wolverine Asset Management's SCVX Position: Q1 2022 in Review

Wolverine Asset Management sold out of SCVX Corp. (SCVX) in Q1 2022, closing a stake of 278,400 shares — an estimated $2.78M sold.

Wolverine Asset Management first reported a position in SCVX in Q2 2020 and held it in 7 quarters. The position peaked at $6.28M in Q3 2020. 5 funds tracked by Wall St. Rank hold SCVX as of Q1 2022.

  • Wolverine Asset Management reported no remaining SCVX Corp. position as of Q1 2022 after selling out during the quarter.
  • Wolverine Asset Management sold 278,400 SCVX Corp. shares in Q1 2022, an estimated $2.78M.
  • Wolverine Asset Management first reported a position in SCVX Corp. in Q2 2020 and held it in 7 quarters.
  • Wolverine Asset Management's SCVX Corp. position peaked at $6.28M in Q3 2020.
  • 5 funds tracked by Wall St. Rank held SCVX Corp. as of Q1 2022.

Based on Wolverine Asset Management's 13F filing for Q1 2022, filed 4 May 2022.